Nektar Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Nektar Therapeutics has a total shareholder equity of $131.0M and total debt of $112.6M, which brings its debt-to-equity ratio to 86%. Its total assets and total liabilities are $398.0M and $267.0M respectively.
Key information
86.0%
Debt to equity ratio
US$112.63m
Debt
Interest coverage ratio | n/a |
Cash | US$303.62m |
Equity | US$130.99m |
Total liabilities | US$267.05m |
Total assets | US$398.03m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0UNL's short term assets ($330.7M) exceed its short term liabilities ($51.3M).
Long Term Liabilities: 0UNL's short term assets ($330.7M) exceed its long term liabilities ($215.8M).
Debt to Equity History and Analysis
Debt Level: 0UNL has more cash than its total debt.
Reducing Debt: 0UNL's debt to equity ratio has increased from 19.2% to 86% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0UNL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0UNL has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 31.9% each year.